The partnership targets a systemic inefficiency in pharmaceutical research: the constant, manual navigation between disconnected datasets and isolated analytical tools. Biomni Lab functions as an Integrated Biology Environment, consolidating AI-driven resources into a unified workspace. By operating within Chugai’s secure digital architecture, the platform’s AI agents assist researchers in complex tasks ranging from single-cell analysis and human genetics to target evaluation.

Sohei Oyama, head of biological technology at Chugai, noted that the increasing scale and complexity of scientific data necessitate specialized tools capable of bridging diverse knowledge sources. For Phylo, the deal represents a significant expansion of its reach after Chugai’s teams served as early adopters of the platform’s open-source iteration. Kexin Huang, CEO of Phylo, stated that the collaboration is intended to move biopharma toward an AI-native operational model, using Chugai’s established R&D infrastructure to demonstrate the practical utility of agentic AI in shortening discovery timelines.